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Background: Bosentan is a dual endothelin receptor antagonist initially introduced for the treatment of pulmonary
arterial hypertension and recently approved for the treatment of digital ulcers in patients with systemic sclerosis
(SSc). Our clinical observations indicate that bosentan therapy may be associated with an increased frequency of
centrofacial telangiectasia (TAE). Here, we sought to analyze the frequency of TAE in patients with SSc who were
treated with either bosentan or the prostacyclin analog iloprost.
Methods: We conducted a retrospective analysis in 27 patients with SSc undergoing therapy with either bosentan
(n = 11) or iloprost (n = 16). Standardized photodocumentations of all patients (n = 27) were obtained at a time point ten
months after therapy initiation and analyzed. A subgroup of patients (bosentan: n = 6; iloprost: n = 6) was additionally
photodocumented prior to therapy initiation, enabling an intraindividual analysis over the course of therapy.
Results: After ten months of therapy patients with SSc receiving bosentan showed a significantly (P = 0.0028) higher
frequency of centrofacial TAE (41.6 ± 27.8) as compared to patients with SSc receiving iloprost (14.3 ± 13.1).
Detailed subgroup analysis revealed that the frequency of TAE in the bosentan group (n = 6 patients) increased
markedly and significantly (P = 0.027) by 44.4 after ten months of therapy (TAE at therapy initiation: 10.8 ± 5.1;
TAE after ten months of therapy: 55.2 ± 29.8), whereas an only minor increase of 1.9 was observed in the iloprost
group (n = 6 patients; TAE at therapy initiation: 18.3 ± 14.5; TAE after ten months of therapy: 20.2 ± 15.5), yet
without reaching statistical significance (P = 0.420).
Conclusions: The use of bosentan may be associated with an increased frequency of TAE in patients with SSc.
Patients should be informed about this potential adverse effect prior to therapy. Treatment options may include
camouflage or laser therapy.
Keywords: Endothelin, Bosentan, Iloprost, Telangiectasia, Systemic sclerosisBackground
Scleroderma (systemic sclerosis, SSc) is a rare autoimmune
disease characterized by excessive extracellular matrix
deposition, fibrosis and vascular alterations [1,2]. The
disorder can affect almost any organ, including the kidneys,
the gastrointestinal tract, lungs or heart, and most not-
ably the skin, and may lead to severe dysfunction up to* Correspondence: bernhard.homey@uni-duesseldorf.de
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reproduction in any medium, provided the orcomplete organ failure [3]. The two major forms of SSc
are localized scleroderma and systemic scleroderma.
Localized scleroderma is the more common form of the
disease and only affects the skin without any internal
organ involvement. By contrast, systemic scleroderma
or systemic sclerosis is characterized by cutaneous and
non-cutaneous involvement and can be further subdivided
into limited cutaneous scleroderma (lcSSc) and diffuse
cutaneous scleroderma (dcSSc). The latter types are defined
with regard to the extent of skin tightening, the number
of affected inner organs as well as their typical autoanti-
body profile. Any combination of SSc and a rheumatologicLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of the subgroups of patients
treated with either iloprost (n = 16) or bosentan (n = 11)
Characteristic Iloprost Bosentan
lcSSc 12 (75%) 5 (45.5%)
dcSSc 2 (12.5%) 5 (45.5%)
Overlap 2 (12.5%) 1 (9%)
CREST+ 8 (50%) 4 (36.4%)
ANA+ 14 (87.5%) 11 (100%)
ACA + (overlap excluded) 5 (35.7%) 3 (30%)
Anti-Scl-70 (overlap excluded) 5 (35.7%) 4 (40%)
Anti-CENP-B (overlap excluded) 2 (14.3%) 2 (20%)
Anti-Ro/SS-A (overlap excluded) 4 (28.6%) 1 (10%)
Anri-Ro/SS-B (overlap excluded) 1 (7.1%) 0
Anti-RNP (−Sm, -70) (overlap excluded) 1 (7.1%) 1 (10%)
Table 2 Co-medication of the subgroups of patients
treated with either iloprost (n = 16) or bosentan (n = 11)
Co-medication Iloprost Bosentan
Calcium channel blockers 10 (62.5%) 7 (63.7%)
Acetyl salicylic acid 7 (43.8%) 6 (54.5%)
Nitrates 3 (18.8%) 2 (18.2%)
β-blockers 1 (6.3%) 3 (27.3%)
Diuretics 2 (12.5%) 3 (27.3%)
ACE-inhibitors 2 (12.5%) 2 (18.2%)
Statins 2 (12.5%) 1 (9.1%)
Systemic steroids 5 (31.3%) 4 (36.4%)
Methotrexate 4 (25%) 1 (9.1%)
Azathioprine 0 (0%) 1 (9.1%)
Analgesics 16 (100%) 10 (90.9%)
Antidepressants 4 (25%) 3 (27.3%)
Proton pump inhibitors 15 (93.8%) 10 (90.9%)
Thyroxine 3 (18.8%) 2 (18.2%)
Warfarin 0 (0%) 1 (9.1%)
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matoid arthritis or Sjögren’s syndrome, is referred to as
overlap syndrome [2-4].
Clinically, digital ulcers and gangrene are a frequent
and chronically recurrent complication of SSc and may
result in considerable disability [5-7]. Of note, the inci-
dence for finger amputation was reported to be as high
as 1.2% per patient-year in patients with SSc affected
by digital ulcers [5]. The main causes of digital ulcers
are SSc-associated vascular alterations [8,9]. Vascular
disease involves the microcirculation and arterioles and
comprises swelling of the intima, intimal proliferation
in the arterioles and distortion of the capillaries with
occasional capillary necrosis. Endothelial apoptosis has
been recognized as an important component of the vas-
cular disease [10,11]. The resulting capillary destruction
leads to a reduced size of microvascular beds, followed
by decreased organ blood flow, eventually resulting in
chronic ischemia. In addition, patients with SSc dem-
onstrate a vascular dysfunction that is characterized by
vascular permeability, a deregulated control of the vascular
tone as well as an activation of the platelets and the
coagulation systems [10,12].
Endothelin is a potent vasoconstrictor that is released
by fibroblasts [13]. Endothelin overexpression has been
associated with various medium- and long-term physio-
logic processes, such as mitogenesis, fibrosis, vascular
hypertrophy, inflammation, and tissue remodeling [14,15].
Additionally, there is now accumulating evidence that
endothelin-1 (ET-1) is a key mediator in the regulation
of the vascular tone. In SSc, the endothelin production
is significantly enhanced, leading to vasoconstriction,
vessel remodeling, local ischemia and formation of ulcers
of the fingertips [16,17]. So far, bosentan represents the
only approved drug for the treatment of SSc-related
symptoms, namely digital ulcers.
The treatment of SSc includes the following objectives:
reduction of vasospastic phenomena, improvement of vas-
cular permeability, counteracting endothelial dysfunction
and antiplatelet action, prevention of visceral involvement,
and improvement in quality of life (QOL) [18-21]. New
specific therapies have been developed targeting prosta-
cyclin and endothelin, two major mediators governing
endothelial function, leading to endothelial dysfunction
[1]. In this context, stable analogs of prostacyclin, like
iloprost, have shown efficacy and improved life expectancy
in patients with SSc [21-23]. The main pharmacological
effects of iloprost are inhibition of platelet aggregation and
vasodilatation. Both effects are mediated by an activity of
adenylate cyclase/cAMP complex, activation of fibrinoly-
sis, and reduced release of free oxygen radicals [24,25].
Bosentan is a dual endothelin receptor antagonist. It
competes with ET-1 by binding to the receptors ET-A
and ET-B, which are localized in the endothelial andmuscle layers of the blood vessel walls. The contribution
of ET-1 to the development of digital ulcers and the effi-
cacy of bosentan therapy in patients with SSc was assessed
in clinical studies by Korn et al. and Matucci-Cerinic et al.
[26,27]. RAPIDS-2 (RAndomized, Placebo-controlled study
on the prevention of Ischemic Digital ulcers secondary
to Scleroderma) demonstrated a reduced incidence of new
digital ulcers in those patients who already had ulcers,
whereas bosentan did not exert any effect on the healing
of ulcers [27]. The results of RAPIDS-2 are also included
in a recent meta-analysis of the healing and prevention of
digital ulcers in patients with SSc by Tingey et al. Notably,
results from studies on iloprost have been similar, demon-
strating no statistically significant effects on the healing or
improvement of digital ulcers in patients with SSc, while
Figure 1 Frequency of centrofacial telangiectasia (TAE) patients
with systemic sclerosis (SSc) treated with bosentan or iloprost over
ten months. Patients receiving bosentan (n = 11) showed a significantly
(P= 0.0028) higher frequency of centrofacial TAE (n = 41.6 ± 27.8) as
compared to TAE in patients receiving iloprost (n = 16; n = 14.8 ± 13.1).
Values are plotted as individual ratios, including mean ratio values shown
by the horizontal bar. Data were evaluated using a Student’s t-test.
Figure 2 Development of centrofacial telangiectasia (TAE) in patients
over ten months. Patients receiving (a) bosentan (n = 6) developed signif
after ten months of therapy: n = 55.2 ± 29.8) as compared to patients receiv
ten months of therapy: n = 20.2 ± 15.5; P = 0.420). Values are plotted as indi
Data were evaluated using a Student’s t-test.
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[28]. In spite of the aforementioned positive effects of
both bosentan and iloprost in the treatment of SSc, few
common, non-serious adverse effects have to be men-
tioned, including vasodilatation leading to flush, headache,
gastrointestinal symptoms, hypotensive reactions, bradycar-
dia or paresthesia. Moreover, bosentan therapy has been
associated with an elevation of the liver aminotransferases
(ALT and AST) as well as bilirubin [29-31].
Our own clinical observations suggest that the frequency
of centrofacial telangiectasia (TAE) may be increased in
patients with SSc treated with bosentan. Here, we sought to
assess the frequency on TAE in patients with SSc treated
with bosentan or iloprost. Results may point toward a
hitherto little-known, in some cases stigmatizing adverse
effect of bosentan therapy.Methods
Patients
We conducted retrospective analysis in 27 Caucasian pa-
tients with SSc (24 female, 3 male; median age 60.9 years,
range 27 to 81 years; median disease duration 13.5 years,
range 2 to 32 years) treated with either iloprost (n = 16) or
bosentan (n = 11). Of these, 17 had lcSSc, 7 had dcSSc and
3 had overlap syndrome, according to the criteria of the
American College of Rheumatology (ACR) and LeRoy et al.
[4]. Patients of the iloprost and bosentan group did not
show relevant differences with regard to gender, age, type
of diseases, profiles of autoantibodies, or co-medications.
The patients’ characteristics are listed in Table 1.with systemic sclerosis (SSc) treated with bosentan or iloprost
icantly (P = 0.027) more TAE (TAE before therapy: n = 10.8 ± 9.5; TAE
ing (b) iloprost (n = 6; TAE before therapy: n = 18.3 ± 14.5; TAE after
vidual ratios, including mean ratio values shown by the horizontal bar.
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Bosentan (Tracleer®, Actelion Ltd., Allschwil, Switzerland)
was administered at a starting dose of 62.5 mg twice
daily and increased to 125 mg twice daily after four
weeks of treatment according to the manufacturer’s
recommendation. Iloprost (Ilomedin®, 20 μg/ml, Schering
AG, Berlin, Germany) was given intravenously, body-
weight adapted (0.5 ng/kg per minute for eight hours
on five successive days), according to the manufacturer’s
recommendation. Patients received additional therapy with
antimalarial and immunosuppressive agents. Other co-
mediations are listed in Table 2.
Assessment of TAE
Standardized photodocumentation of all patients was
performed after ten months of therapy after obtaining
informed consent. After we had initially observed a po-
tentially higher incidence of TAE in patients treated with
bosentan, new patients referring to our department for
bosentan or iloprost therapy were photodocumented also
prior to the initiation of therapy. This subgroup (n = 12)Figure 3 Clinical appearance centrofacial telangiectasia (TAE) in patie
(a-c) 57-year-old man treated with bosentan; (d-f) 54-year-old woman treadid not show any relevant differences (for example. gender,
age, disease characteristics, duration of therapy) with regard
to the rest of the cohort. For the assessment of TAE,
digitized images were edited with monochrome and
red-adjustment. All images were obtained and digitized
for blinded reading.
Statistical methods
Data were evaluated using Student’s t-tests. For com-
paring the overall difference for patients treated with
bosentan and patients treated with iloprost, a P-value
from a two-sided Student’s t-test was calculated. An
addition, multivariate linear regression models with
frequency of TAE as response variable and treatment
(bosentan versus iloprost) in combination with other
clinical factors as explanatory variables were calcu-
lated. In order to investigate treatment effects over time
within the subgroups of patients for both therapies sep-
arately, paired Student’s t-tests were conducted. Re-
ported P-values for Student’s t-tests were corrected for
multiple comparisons by considering the conservativents treated with bosentan or iloprost after ten months.
ted with iloprost.
Figure 4 Clinical appearance centrofacial telangiectasia (TAE) in
patients treated with iloprost or bosentan after ten months.
(a) Close-up and (b) diascopy of the cheek of a 57-year-old man
treated with bosentan; (c) close-up of the cheek of 54-year-old woman
treated with iloprost.
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declared to be significant.
Results
Frequency of TAE
After ten months, patients treated with bosentan (n = 11
patients) showed a significantly (P = 0.0028) higher fre-
quency of centrofacial TAE (n = 41.6 ± 27.8) as compared
to patients receiving iloprost (n = 16 patients; n = 14.3 ±
13.1) (Figure 1). Multivariate linear regression analyses
show that in the presence of other clinically assessed fac-
tors, treatment (bosentan versus iloprost) remains the only
significant predictor for the frequency of TAE (P = 0.099)
after adjusting for lcSSc and dcSSc (P = 0.017 after adjust-
ing for all clinical factors presented in Table 1). A pro-
spective sub-group analysis of the frequency of TAE
prior to and after ten months of therapy demonstrated
a significant (P = 0.027) increase in the bosentan group
(n = 6 patients; TAE before therapy: n = 10.8 ± 5.1; TAE
after ten months of therapy: n = 55.2 ± 29.8) (Figure 2a)
as compared to the iloprost group (n = 6 patients; TAE
before therapy: n = 18.3 ± 14.5; TAE after ten months of
therapy: n = 20.2 ± 15.5; P = 0.420) (Figure 2b). Whereas
the majority of patients in the bosentan group reported
a fast or rapid development of TAE after initiation of
the bosentan therapy and suspected a likely correlation
to the drug, patients of the iloprost group reported a
progressive development of TAE over several years and
suspected a correlation to the progression of the SSc
disease, not the drug.
Appearance of TAE
TAE in bosentan patients had a rather dotted clinical
appearance and showed a tendency to persist under
diascopic pressure, whereas iloprost patients had rather
linear or elongated TAE which tended to fade under
diascopic pressure (Figures 3 and 4). The two patients
with the most rapid development of TAE discontinued
bosentan therapy due to the stigmatizing aspect of
the lesions. These two patients did not exhibit any
additional special characteristics as compared to the
remaining cohort.
Discussion
The ET-1 receptor antagonist bosentan and the prostacyc-
lin analog iloprost are well established in the management
of Raynaud’s phenomenon and ischemic ulcers in patients
with SSc [3,25,27,28,32]. The most important documented
adverse effects of iloprost include flushing, photosensi-
tivity, jaw pain, headaches, diarrhea, nausea and vomiting
[28,33]. Documented adverse effects of bosentan comprise
pruritus, urticaria, leukocytoclastic vasculitis, indurated
erythema, flushing, peripheral edema, elevated amino-
transferases, headache, dizziness, cough, nasal congestionand a potential worsening of symptoms in heart failure
patients [27,28,34-37]. Interestingly, even though flushing
is a known adverse effect of bosentan, persistent alterations
of the facial vasculature such as TAE, have remained
largely unnoticed.
TAE are a characteristic feature of connective tissue dis-
eases such as SSc, dermatomyositis and overlap syndromes
[4,38]. Indeed, they reflect one of the cardinal symptoms
of CREST syndrome (Calcinosis, Raynaud’s phenomenon,
Esophageal dysmotility, Sclerodactyly, TAE). Whereas some
authors state that the acronym CREST is obsolete, others
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(lcSSc) [2,39]. Hence, the observation of TAE in our cohort
of patients with SSc is not surprising. Yet, while it cannot
be ruled out that the increase in the number of TAE is a
consequence of a worsening of the disease over the course
of the therapy, the frequency and rapid progression of TAE
in patients with SSc treated with bosentan is remarkable.
This hypothesis is supported by the fact that patients
treated with bosentan suspected that the onset of TAE
correlated to the administration of the drug, whereas
no such correlations were suspected by patients treated
with iloprost. A further limitation of our study is the small
number of patients included. Yet, our results are in line
with a recent case report by Tong and Kumarasinghe in a
76-year-old woman treated with bosentan for four years.
In this patient, a prominent flushing gradually progressed
to persistent redness and TAE [37].
The molecular and cellular mechanisms governing the
development of TAE in SSc, as well as the mechanisms by
which bosentan may induce persistent vascular alterations,
have remained largely elusive. It has been proposed that
TAE in SSc develop as a response to endothelial injury.
This concept is supported by micro-capillaroscopic ana-
lyses that reveal an extensive derangement and destruction
of the microvasculature in a variety of organ systems [38].
Interestingly, the distribution and appearance of TAE
in SSc correspond to TAE in patients with hereditary
hemorrhagic telangiectasia (HHT; Osler-Weber-Rendu
syndrome), pointing toward similar pathogenetic mech-
anisms. HHT is an autosomal dominant disorder of the
vasculature development characterized by TAE and arterio-
venous malformations [40]. Abnormal TGF-β signaling has
been shown to play a crucial role in the pathogenesis of
HHT [41]. Moreover, TGF-β signaling has been recognized
as a key regulator of wound healing and fibrosis and exerts
a variety of effects on the biology of endothelial cells
and vascular tissue [1]. Likewise van Royen et al. could
show that exogenous TGF-β stimulated the angiogenesis
in the peripheral circulation in an in vivo rabbit model
[42]. Interestingly, patients with SSc show elevated serum
levels of connective tissue growth factor (CTGF), a down-
stream target of TGF-β, and scleroderma fibroblasts show
an increased expression of the TGF-β receptor [43,44].
Therefore, it is tempting to speculate that TGF-β signaling
may also play a role in the pathogenesis of TAE in patients
with SSc [38].
With regard to ET-1 antagonists, a recent case report
demonstrated a significant alteration of the macrovascular
involvement by bosentan in a 50-year-old Japanese patient
with SSc. Magnetic resonance angiography showed an
attenuation of a stenosis of the ulnar artery. The authors
concluded that bosentan, besides reversing the vasocon-
strictive effects of ET-1, also exerts remodeling effects on
the vasculature [45]. Accordingly, ET-1 has been shown tocontribute to the mitogenic activity of fibroblasts and
smooth muscle cells in vitro [46,47]. Hence, the promo-
tion of TAE development by bosentan in patients with SSc
may be the result of vasodilatatory and/or direct vascular
remodeling effects.
Conclusions
In summary, we here show that bosentan therapy may be
associated with a significant increase in the number of facial
TAE. Because these stigmatizing lesions are a potential
obstacle to patients’ adherence to therapy, they should
be informed about this adverse effect that has remained
largely unrecognized until recently. Management options
may include camouflage ointment or laser therapy.
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